Bladder cancer: State-of-the-art care

Ca-A Cancer Journal for Clinicians

Volumn 48, Issue 5, 1998, Pages 269-284

  Droller, Michael J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; MITOMYCIN C; THIOTEPA; VINBLASTINE;

BLADDER CANCER; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER STAGING; CLINICAL FEATURE; DEMOGRAPHY; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031711332     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.48.5.269     Document Type: Review

References (73)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Heney NM, Ahmed S, Flanagan MJ, et al: Superficial bladder cancer: Progression and recurrence. J Urol 1983;130:1083-1086.
3. Kaye KW, Lange PH: Mode of presentation of invasive bladder cancer: Reassessment of the problem. J Urol 1982;128:31-33.
4. Prout GR Jr, Griffin PP, Shipley WU: Bladder carcinoma as a systemic disease. Cancer 1979;43:2532-2539.
5. Rehn L: Blasengeschwulte bei Fuchsin-Arbeitern. Arch Klin Chir 1895;50:588.
6. Hueper WC, Wiley FH, Wolfe HD: Experimental production of bladder tumors in dogs by administration of beta-naphthylamine. Hyg Tox 1938;20:46.
7. Case RAM, Hosker ME, McDonald DB, et al: Tumours of the urinary bladder in workmen engaged in the British chemical industry. Role of aryl benzidine, alpha-naphthylamine, and beta-naphthylamine. Br J Intern Med 1954;11:75.
8. Morrison AS, Buring JE, Verhoeck WG, et al: An international study of smoking and bladder cancer. J Urol 1984;131:650-654.
9. Clavel J, Cordier S, Boccon-Gibod L, et al: Tobacco and bladder cancer in males: Increased risk for inhalers and smokers of black tobacco. Int J Cancer 1989;44:605-610.
10. Vineis P, Esteve J, Hange P, et al: Effects of timing and type of tobacco in cigarette-induced bladder cancer. Cancer Res 1998;48:3849-3852.
11. Ellwein LB, Cohen SM: The health risks of saccharin revisited. Crit Rev Toxicol 1990;20:311-326.
12. Cartwright RA, Glashan RW, Rogers HJ, et al: The role of N-acetyltransferase in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982;2:842-845.
13. Mommsen S, Barfod NM, Aagaard J: N-acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population. Carcinogenesis 1985;6:199-201.
14. Bartsch H, Caporaso N, Coda M, et al: Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. J Natl Cancer Inst 1990;82:1826-1831.
15. Varkarakis MJ, Gaeta J, Moore RH, et al: Superficial bladder tumor: Aspects of clinical progression. Urology 1974;4:414-420.
16. Badalament RA, Fair WR, Whitmore WF Jr, et al: The relative value of cytometry and cytology in the management of bladder cancer: The Memorial Sloan-Kettering Cancer Center experience. Semin Urol 1988;6:22-30.
17. Sarosdy MF, deVere White RW, Soloway MS, et al: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 1995;154:379-383.
18. Sarosdy MF, Hudson MA, Ellis WJ, et al: Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology 1997;50:349-353.
19. Droller MJ: Commentary on Sarosdy MF et al: Improved detection of recurrent bladder cancer using the Bard BTA test. J Urol 1998;159:601.
20. Soloway MS, Briggman V, Carpinito GA, et al: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996;156:363-367.
21. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, et al: Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998;159:394.
22. Lin Y, Miyamoto H, Fujinami K, et al: Telomerase activity in human bladder cancer. Clin Cancer Res 1996;2:929-932.
23. Kavaler E, Landman J, Chang Y, et al: Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 1998;82:708-714.
24. Schmetter BS, Habicht KK, Lamm DL, et al: A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997;158:801-805.
25. Lokeshwar V, Phan H, Obeck C, et al: HA-HAase urine test for detecting bladder cancer and evaluating its grade. J Urol 1997;157(Suppl):341.
26. Huland E, Huland H, Meier T, et al: Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder. J Urol 1991;146:1631-1636.
27. Hall RR, Beynon LL, Horwich A, et al: Urology and the TNM classification. Lancet 1988;1:1145-1146.
28. Hermanek P, Sobin LH: UICC-International Union Against Cancer TNM Classification of Malignant Tumors. Heidelberg, Germany, Springer Verlag, 1987, p 133.
29. Droller MJ: Bladder cancer. Curr Probl Surg 1981;18:205-279..
30. Jones PA, Droller MJ: Pathways of development and progression in bladder cancer: New correlations between clinical observations and molecular mechanisms. Semin Urol 1993;11:177-192.
31. Fitzpatrick JM: Superficial Bladder Cancer: Natural History, Evaluation, and Management. Houston, American Urological Association, Inc., 1989. AUA Update Series.
32. Jakse G, Loidl W, Seeber G, et al: Stage T1, grade 3 transitional cell carcinoma of the bladder: An unfavorable tumor? J Urol 1987;137:39-43.
33. Abel PD: Follow-up of patients with 'superficial' transitional cell carcinoma of the bladder: The case for a change in policy. Br J Urol 1993;72:135-142.
34. Prout GR Jr, Barton BA, Griffin PP, et al: Treated history of noninvasive grade 1 transitional cell carcinoma: The National Bladder Cancer Group. J Urol 1992;148:1413-1419.
35. Birch BR, Harland SJ: The pT1 G3 bladder tumour. Br J Urol 1986;64:109-116.
36. Bostwick DG: Natural history of early bladder cancer. J Cell Biochem Suppl 1992;161:31-38.
37. Kakizoe T, Tobisu K, Takai K, et al: Relationship between papillary and nodular transitional cell carcinoma in the human urinary bladder. Cancer Res 1988;48:2299-2303.
38. Pomerance A: Pathology and prognosis following total cystectomy for carcinoma of the bladder. Br J Urol 1972;44:451-458.
39. Kakizoe T, Matumoto K, Nishio Y, et al: Significance of carcinoma in situ and dysplasia in association with bladder cancer. J Urol 1985;133:395-398.
40. Aprikian AG, Sarkis AS, Reuter VE, et al: Biological markers of prognosis in transitional cell carcinoma of the bladder: Current concepts. Semin Urol 1993;11:137-144.
41. Hopman AH, Moesker O, Smeets AW, et al: Numerical chromosome 1, 7, 9, and 11 alterations in bladder cancer detected by in situ hybridization. Cancer Res 1991;51:646-651.
42. Tsai YC, Nichols PW, Hiti AL, et al: Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 1990;50:44-47.
43. Sidransky D, Messing E: Molecular genetics and biochemical mechanisms in bladder cancer: Oncogenes, tumor suppressor genes, and growth factors. Urol Clin North Am 1992;19:629-639.
44. Raghavan D, Shipley WU, Garnick MB, et al: Biology and management of bladder cancer. N Engl J Med 1990;322:1129-1138.
45. Soto EA, Friedell GH, Tiltman AJ: Bladder cancer as seen in giant histologic sections. Cancer 1977;39:447-455.
46. Prout GR Jr, Griffin PP, Shipley WU: Bladder carcinoma as a systemic disease. Cancer 1979;43:2532-2539.
47. Melicow MM: Histological study of vesical urothelium intervening between gross neoplasm in total cystectomy. J Urol 1952;68:261.
48. Hudson MA, Herr HW: Carcinoma in situ of the bladder. J Urol 1995;153:564-572.
49. Lamm DL: Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992;19:573-580.
50. Lamm DL, van der Meijden AP, Akaza H, et al: Intravesical chemotherapy and immunotherapy: How do we assess their effectiveness and what are their limitations and uses? Int J Urol 1995;2(Suppl 2):23-35.
51. Althausen AF, Prout GR Jr, Daly JJ: Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976;116:575-580.
52. Klän R, Loy V, Huland H: Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 1991;146:316-318.
53. Brosman SA, Lamm DL: The preparation, handling and use of intravesical bacillus Calmette-Guérin for the management of stage Ta, T1, carcinoma in situ and transitional cell cancer. J Urol 1990;144:313-315.
54. Lamm DL: Carcinoma in situ. Urol Clin North Am 1992;19:499-508.
55. Lamm DL, Steg A, Boccon-Gibod L, et al: Complications of bacillus Calmette-Guérin immunotherapy: Review of 2602 patients and comparison of chemotherapy complications. Prog Clin Biol Res 1989;310:335-355.
56. Merz VW, Marth D, Kraft R, et al: Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder. Br J Urol 1995;75:180-184.
57. Herr HW, Schwalb DM, Zhang ZF, et al: Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995;13:1404-1408.
58. 4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor: DAVECA Protocol 8201: Danish Vesical Cancer Group. Scand J Urol Nephrol Suppl 1991;138:193-201.
59. Skinner DG, Lieskovsky G: Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J Urol 1984;131:1069-1072.
60. Messing EM, Young TB, Hunt VB, et al: The significance of asymptomatic microhematuria in men 50 or more years old: Findings of a home screening study using urinary dipsticks. J Urol 1987;137:919-922.
61. Howard RS, Golin AL: Long-term follow-up of asymptomatic microhematuria. J Urol 1991;145: 335-336.
62. Sternberg CN, Yagoda A, Scher HI, et al: MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988;139:461-469.
63. Harker WG, Meyers FJ, Freiha FS, et al: Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: A Northern California Oncoloyy Group study. J Clin Oncol 1985;3:1463-1470.
64. Logothetis CJ, Dexeus FH, Finn L, et al: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8:1050-1055.
65. Martinez-Piñeiro JA, Gonzalez Martin M, Arocena F, et al: Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: A prospective randomized phase III study. J Urol 1995;153:964-973.
66. Hall RR: Bladder preserving treatment: The role of transurethral surgery alone and with combined modality therapy for muscle-invading bladder cancer, in Vogelzang NJ, Scardino PT, Shipley WU (eds): Comprehensive Textbook of Genitourinary Oncology. Baltimore, Williams & Wilkins. 1995. p 509.
67. Prout GR Jr, Shipley WU, Kaufman DS, et al: Interval report of a phase I-II study utilizing multiple modalities in the treatment of invasive bladder cancer: A bladder-sparing trial. Urol Clin North Am 1991;18:547-554.
68. Wajsman Z, Marino R, Parsons J, et al: Bladder-sparing approach in the treatment of invasive bladder cancer. Semin Urol 1990;8:210-215.
69. Herr HW: Conservative management of muscle-infiltrating bladder cancer: Prospective experience. J Urol 1987;138:1162-1163.
70. Solsona E, Iborra I, Ricos, JV, et al: Feasibility of transurethral resection for muscle-infiltrating carcinoma of the bladder: Prospective study J Urol 1992;147:1513-1515.
71. Slack NH, Prout GR Jr: Heterogeneity of invasive bladder carcinoma and different responses to treatment, in Bonney WW, Prout GR (eds): Bladder Cancer. Baltimore, Williams & Wilkins. 1980. p 213. AUA Monographs, vol. 1.
72. Jewett HJ, Strong GH: Infiltrating carcinoma of the bladder: Relation of depth of penetration of the bladder wall to incidence of local extension and metastases. J Urol 1946;55:366.
73. Koss LG: Tumors of the Urinary Bladder. Washington, DC. Armed Forces Institute of Pathology. 1974. Atlas of Tumor Pathology. Second Series. Fascicle 11.